1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2020, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.
Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 15 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.
Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionVancomycin-Resistant Enterococcus faecium Infections - Overview
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Development
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment
Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development
Vancomycin-Resistant Enterococcus faecium Infections - Drug Profiles
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products
Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Acurx Pharmaceuticals LLC, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AimMax Therapeutics Inc, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AnyGen Co Ltd, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Arietis Corp, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Armata Pharmaceuticals, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Curza Global LLC, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix Inc, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Karveel Pharmaceuticals, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences Inc, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Ltd, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals Inc, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Naicons Srl, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Opal Biosciences Ltd, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by QureTech Bio AB, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Rebiotix Inc, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA GMBH, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals Inc, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acurx Pharmaceuticals LLC
- AimMax Therapeutics Inc
- AnyGen Co Ltd
- Aphios Corp
- Arietis Corp
- Armata Pharmaceuticals
- Curza Global LLC
- Daiichi Sankyo Co Ltd
- Helix BioMedix Inc
- Hsiri Therapeutics LLC
- Karveel Pharmaceuticals
- LegoChem Biosciences Inc
- MGB Biopharma Ltd
- MicuRx Pharmaceuticals Inc
- Naicons Srl
- NovoBiotic Pharmaceuticals LLC
- Opal Biosciences Ltd
- Oragenics Inc
- QureTech Bio AB
- Rebiotix Inc
- Sealife PHARMA GMBH
- Sentinella Pharmaceuticals Inc
- Wockhardt Ltd
